France's NicOx has decided to move ahead in the development of NCX 4016 as a therapy for Type 2 diabetes. Researchers will launch two Phase II trials of the therapy with an eye to confirming the drug's efficacy against diabetes. Earlier data from clinical trials has demonstrated its ability to release higher, more sustained levels of salicylate than had been earlier thought, says NicOx.
"There is a solid scientific rationale supporting the development of NCX 4016 as an insulin sensitizing agent, based on the known effects of nitric oxide and salicylate and the recent finding that NCX 4016 releases higher and more sustained levels of salicylate than previously thought," said Maarten Beekman, Vice President of Clinical Development at NicOx. "Clinical results also suggest these mechanisms may benefit the vascular complications of type 2 diabetes and we hope to develop NCX 4016 as a new oral treatment for this very serious and prevalent disease."
- take a look at the report on Nicox from Trading Markets